Regeneron Pharmaceuticals (NASDAQ: REGN) slid Wednesday after Ophthotech announced positive results from a trial of wet age-related macular degeneration. Ophthotech's drug would compete with Regeneron's Eylea. ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)